Showing 1 - 14 results of 14 for search 'Myron J Levin', query time: 0.03s Refine Results
  1. 1
    Immune responses to zoster vaccines

    Immune responses to zoster vaccines by Myron J Levin, Adriana Weinberg

    Published 2019-04-01
    Get full text
    Article
  2. 2
    Absenteeism and Productivity Loss Due to Influenza or Influenza-like Illness in Adults in Europe and North America

    Absenteeism and Productivity Loss Due to Influenza or Influenza-like Illness in Adults in Europe and North America by David Fisman, Maarten Postma, Myron J. Levin, Joaquin Mould-Quevedo

    Published 2024-12-01
    Get full text
    Article
  3. 3
    Development of antibody-dependent cellular cytotoxicity in response to recombinant and live-attenuated herpes zoster vaccines

    Development of antibody-dependent cellular cytotoxicity in response to recombinant and live-attenuated herpes zoster vaccines by Seong Yeon Park, Myron J. Levin, Jennifer Canniff, Michael Johnson, D. Scott Schmid, Adriana Weinberg

    Published 2022-10-01
    Get full text
    Article
  4. 4
    Studies with herpes zoster vaccines in immune compromised patients

    Studies with herpes zoster vaccines in immune compromised patients by Myron J. Levin, Eddy Bresnitz, Zoran Popmihajlov, Adriana Weinberg, Kai-Li Liaw, English Willis, Jeffrey R. Curtis

    Published 2017-12-01
    Get full text
    Article
  5. 5
    Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults

    Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults by Adriana Weinberg, Stacie L Lambert, Jennifer Canniff, Li Yu, Nancy Lang, Mark T Esser, Judith Falloon, Myron J Levin

    Published 2019-10-01
    Get full text
    Article
  6. 6
    Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis

    Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influ... by Myron J. Levin, Victoria Divino, Drishti Shah, Mitch DeKoven, Joaquin Mould-Quevedo, Stephen I. Pelton, Maarten J. Postma

    Published 2021-10-01
    Get full text
    Article
  7. 7
    A clinical and economic assessment of adjuvanted trivalent versus standard egg-derived quadrivalent influenza vaccines among older adults in the United States during the 2018-19 and 2019-20 influenza seasons

    A clinical and economic assessment of adjuvanted trivalent versus standard egg-derived quadrivalent influenza vaccines among older adults in the United States during the 2018-19 an... by Myron J. Levin, Victoria Divino, Maarten J. Postma, Stephen I. Pelton, Zifan Zhou, Mitch DeKoven, Joaquin Mould-Quevedo

    Published 2024-12-01
    Get full text
    Article
  8. 8
    A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18–64 Years in the United States

    A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18–64 Years in the United States by Myron J. Levin, Neda Al Rawashdh, Liliane Mofor, Pablo Anaya, Richard M. Zur, Emily B. Kahn, Daniel Yu, Joaquin F. Mould-Quevedo

    Published 2024-10-01
    Get full text
    Article
  9. 9
    The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses

    The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses by David Fisman, Norberto Giglio, Myron J. Levin, Van Hung Nguyen, Stephen I. Pelton, Maarten Postma, Jesús Ruiz-Aragón, Analia Urueña, Joaquin F. Mould-Quevedo

    Published 2024-12-01
    Get full text
    Article
  10. 10
    Evaluation of two frailty indices, with practical application in a vaccine clinical trial

    Evaluation of two frailty indices, with practical application in a vaccine clinical trial by Desmond Curran, Melissa K. Andrew, Myron J. Levin, Elisa Turriani, Sean Matthews, Charles Fogarty, Nicola P. Klein, Katrijn Grupping, Lidia Oostvogels, Kenneth E. Schmader

    Published 2019-12-01
    Get full text
    Article
  11. 11
    Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials

    Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials by Myron J. Levin, Andrew Ustianowski, Stephane De Wit, Rohini Beavon, Jesse Thissen, Seth Seegobin, Kanika Dey, Karen A. Near, Katie Streicher, Alexandre Kiazand, Mark T. Esser

    Published 2024-05-01
    Get full text
    Article
  12. 12
    Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials

    Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials by Romulo Colindres, Valentine Wascotte, Alain Brecx, Christopher Clarke, Caroline Hervé, Joon Hyung Kim, Myron J. Levin, Lidia Oostvogels, Toufik Zahaf, Anne Schuind, Anthony L. Cunningham

    Published 2020-11-01
    Get full text
    Article
  13. 13
    Broadly reactive human CD8 T cells that recognize an epitope conserved between VZV, HSV and EBV.

    Broadly reactive human CD8 T cells that recognize an epitope conserved between VZV, HSV and EBV. by Christopher Chiu, Megan McCausland, John Sidney, Fuh-Mei Duh, Nadine Rouphael, Aneesh Mehta, Mark Mulligan, Mary Carrington, Andreas Wieland, Nicole L Sullivan, Adriana Weinberg, Myron J Levin, Bali Pulendran, Bjoern Peters, Alessandro Sette, Rafi Ahmed

    Published 2014-03-01
    Get full text
    Article
  14. 14
    Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials

    Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials by Lidia Oostvogels, Thomas C. Heineman, Robert W. Johnson, Myron J. Levin, Janet E. McElhaney, Peter Van den Steen, Toufik Zahaf, Alemnew F. Dagnew, Roman Chlibek, Javier Diez-Domingo, Iris S. Gorfinkel, Caroline Hervé, Shinn-Jang Hwang, Hideyuki Ikematsu, George Kalema, Himal Lal, Shelly A. McNeil, Tomas Mrkvan, Karlis Pauksens, Jan Smetana, Daisuke Watanabe, Lily Yin Weckx, Anthony L. Cunningham

    Published 2019-12-01
    Get full text
    Article

Search Tools: